From GlobeNewswire:

Cogent Biosciences announced that Andrew Robbins, CEO, will present at the J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will feature bezuclastinib, a targeted therapy for diseases caused by genetic mutations. A live webcast will be available on the Cogent Biosciences website, with a replay for up to 30 days.

The most advanced clinical program at Cogent Biosciences is bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit certain genetic mutations. These mutations are found in patients with systemic mastocytosis or gastrointestinal stromal tumors (GIST). The Cogent Research Team is also developing other targeted therapies for patients with genetically driven diseases based in Waltham, MA and Boulder, CO.

For more information, visit the Cogent Biosciences website, and follow them on social media for updates. For media inquiries, contact Christi Waarich, Senior Director of Investor Relations via email or phone.



Read more: Cogent Biosciences Announces Presentation at the 42nd